David Horn Solomon joined Pharnext SA, a clinical-stage biopharmaceutical company that is developing new drug combinations based on big genomic data and artificial intelligence, in April 2020. He told In Vivo in an exclusive interview that he was attracted to Pharnext, a company that had been struggling with manufacturing challenges for its lead pipeline candidate, because of the clinical data it had produced for the rare disease Charcot-Marie-Tooth. There are no currently approved therapies for the disease.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?